SI3551209T1 - Inzulin-FC fuzije in postopki uporabe - Google Patents

Inzulin-FC fuzije in postopki uporabe

Info

Publication number
SI3551209T1
SI3551209T1 SI201730909T SI201730909T SI3551209T1 SI 3551209 T1 SI3551209 T1 SI 3551209T1 SI 201730909 T SI201730909 T SI 201730909T SI 201730909 T SI201730909 T SI 201730909T SI 3551209 T1 SI3551209 T1 SI 3551209T1
Authority
SI
Slovenia
Prior art keywords
fusions
insulin
methods
Prior art date
Application number
SI201730909T
Other languages
English (en)
Inventor
Thomas M Lancaster
Todd C Zion
Thillainayagam Sathiyaseelan
Sylaja Murikipudi
Original Assignee
Akston Biosciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akston Biosciences Corp filed Critical Akston Biosciences Corp
Publication of SI3551209T1 publication Critical patent/SI3551209T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SI201730909T 2016-12-09 2017-12-08 Inzulin-FC fuzije in postopki uporabe SI3551209T1 (sl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662432268P 2016-12-09 2016-12-09
US201762514460P 2017-06-02 2017-06-02
US201762514449P 2017-06-02 2017-06-02
US201762514427P 2017-06-02 2017-06-02
EP17878116.7A EP3551209B1 (en) 2016-12-09 2017-12-08 Insulin-fc fusions and methods of use
PCT/US2017/065456 WO2018107117A1 (en) 2016-12-09 2017-12-08 Insulin-fc fusions and methods of use

Publications (1)

Publication Number Publication Date
SI3551209T1 true SI3551209T1 (sl) 2021-10-29

Family

ID=62491387

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201730909T SI3551209T1 (sl) 2016-12-09 2017-12-08 Inzulin-FC fuzije in postopki uporabe

Country Status (13)

Country Link
US (2) US11359001B2 (sl)
EP (2) EP3551209B1 (sl)
JP (2) JP7170332B2 (sl)
CN (1) CN110612112B (sl)
AU (2) AU2017371217B2 (sl)
BR (1) BR112019011860A2 (sl)
CA (1) CA3046337C (sl)
DK (1) DK3551209T3 (sl)
HR (1) HRP20211334T1 (sl)
HU (1) HUE055417T2 (sl)
LT (1) LT3551209T (sl)
SI (1) SI3551209T1 (sl)
WO (1) WO2018107117A1 (sl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE055417T2 (hu) 2016-12-09 2021-11-29 Akston Biosciences Corp Inzulin-Fc fúziók és alkalmazási eljárások
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
EP3892628B1 (en) * 2018-06-29 2022-09-07 Akston Biosciences Corporation Ultra-long acting insulin-fc fusion proteins and methods of use
SG11202106168VA (en) * 2018-12-11 2021-07-29 Sanofi Sa Insulin analogs having reduced insulin receptor binding affinity
WO2021011827A1 (en) * 2019-07-16 2021-01-21 Akston Biosciences Corporation Ultra-long acting insulin-fc fusion proteins and methods of use
FI4073098T3 (fi) * 2019-12-19 2023-11-15 Akston Biosciences Corp Ultrapitkävaikutteiset insuliini-Fc-fuusioproteiinit ja niiden käyttömenetelmät
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
HRP20230990T1 (hr) 2020-04-10 2023-12-08 Akston Biosciences Corporation Antigen specifična imunoterapija za fuzijske proteine covid-19 i postupci uporabe
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
JP7532638B2 (ja) 2020-07-24 2024-08-13 チアンスー ジェンサイエンス インコーポレイテッド インスリン-Fc融合タンパク質及びその応用
EP4373861A2 (en) 2021-07-23 2024-05-29 Akston Biosciences Corporation Insulin-fc fusion proteins and methods of use to treat cancer
CN115894720B (zh) * 2023-01-16 2024-07-09 中国科学院上海药物研究所 一种长效胰岛素-Fc融合蛋白

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JPH07116160B2 (ja) 1987-08-10 1995-12-13 浜理薬品工業株式会社 結晶性l−カルノシン亜鉛錯体およびその製造法
EP1132471A3 (de) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
CN1125081C (zh) * 1999-09-08 2003-10-22 中国科学院上海生物化学研究所 重组天然和新型人胰岛素及其制备方法
US20030040601A1 (en) * 2001-06-08 2003-02-27 Ivan Diers Method for making insulin precursors and insulin analog precursors
US8569231B2 (en) * 2009-03-20 2013-10-29 Smartcells, Inc. Soluble non-depot insulin conjugates and uses thereof
CA2754408A1 (en) 2009-03-30 2010-10-14 Boehringer Ingelheim International Gmbh Fusion proteins comprising canine fc portions
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
CN101891823B (zh) 2010-06-11 2012-10-03 北京东方百泰生物科技有限公司 一种Exendin-4及其类似物融合蛋白
EP2598170A4 (en) * 2010-07-28 2016-07-06 Smartcells Inc MEDICAMENT-LIGAND CONJUGATES, THEIR SYNTHESIS AND CORRESPONDING INTERMEDIATES
JP2013535467A (ja) * 2010-07-28 2013-09-12 スマートセルズ・インコーポレイテツド 組換えにより発現されたインスリンポリペプチドおよびその使用
BR112013032265A2 (pt) * 2011-06-17 2016-12-20 Halozyme Inc métodos de infusão de insulina subcutânea contínua com uma enzima de degradação do hialuronano
AR087433A1 (es) * 2011-08-08 2014-03-26 Merck Sharp & Dohme Analogos de insulina n-glicosilados
JP2014533249A (ja) 2011-11-07 2014-12-11 メディミューン,エルエルシー 多重特異性を持つ多価結合タンパク質およびその使用
WO2013074598A1 (en) 2011-11-18 2013-05-23 Merck Sharp & Dohme Corp. Fc CONTAINING POLYPEPTIDES HAVING INCREASED ANTI-INFLAMMATORY PROPERTIES AND INCREASED FcRN BINDING
KR102041412B1 (ko) 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Fc 단편 유도체
CN103509118B (zh) 2012-06-15 2016-03-23 郭怀祖 胰岛素-Fc融合蛋白
EP3616727B1 (en) 2013-02-26 2021-03-31 Hanmi Pharm. Co., Ltd. Insulin analog conjugates and use thereof
EP3194429A4 (en) 2014-09-18 2018-06-13 Askgene Pharma, Inc. Novel feline erythropoietin receptor agonists
WO2016105545A2 (en) 2014-12-24 2016-06-30 Case Western Reserve University Insulin analogues with enhanced stabilized and reduced mitogenicity
EP3250589A4 (en) 2015-01-29 2018-06-20 Nexvet Australia Pty Ltd Therapeutic and diagnostic agents
JP2018508504A (ja) 2015-02-17 2018-03-29 ハンミ ファーマシューティカル カンパニー リミテッド 持続型インスリンまたはインスリンアナログ結合体
CN107709355B (zh) 2015-05-04 2021-09-14 阿珀吉尼科斯股份公司 单链cd40受体激动剂蛋白
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
CN107743494B (zh) 2015-06-02 2022-04-29 诺和诺德股份有限公司 具有极性重组延伸体的胰岛素
EP3757119A1 (en) 2015-11-16 2020-12-30 Ubiprotein, Corp. A method for extending half-life of a protein
EP3481413A4 (en) 2016-07-08 2020-01-08 Askgene Pharma, Inc. FUSION PROTEIN WITH LEPTIN AND METHOD FOR THE PRODUCTION AND USE THEREOF
BR112019005637A2 (pt) 2016-09-23 2019-07-30 Hanmi Pharm Ind Co Ltd análogos da insulina com afinidade reduzida para o receptor de insulina e seu uso
EP3526246A1 (en) 2016-10-17 2019-08-21 Vetoquinol SA Modified antibody constant region
HUE055417T2 (hu) 2016-12-09 2021-11-29 Akston Biosciences Corp Inzulin-Fc fúziók és alkalmazási eljárások
AR111122A1 (es) 2017-03-07 2019-06-05 Univ Case Western Reserve Análogos de insulina de cadena única estabilizados por un cuarto puente disulfuro
JP2020531002A (ja) 2017-08-15 2020-11-05 キンドレッド バイオサイエンシズ インコーポレイテッド 獣医学用igg fc変異体
WO2019204206A1 (en) 2018-04-16 2019-10-24 Chou Danny Hung Chieh Glucose-responsive insulin
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
EP3892628B1 (en) 2018-06-29 2022-09-07 Akston Biosciences Corporation Ultra-long acting insulin-fc fusion proteins and methods of use
CA3114395A1 (en) 2018-09-25 2020-04-02 Absci, Llc Protein purification methods
AR116605A1 (es) 2018-10-05 2021-05-26 Novo Nordisk As Compuestos bifuncionales que comprenden péptidos de insulina y péptidos de egf(a)
US20220002373A1 (en) 2018-11-19 2022-01-06 Case Western Reserve University Single-chain insulin analogues with poly-alanine c-domain sub-segments
WO2020236762A2 (en) 2019-05-17 2020-11-26 Case Western Reserve University Variant single-chain insulin analogues
WO2021011827A1 (en) 2019-07-16 2021-01-21 Akston Biosciences Corporation Ultra-long acting insulin-fc fusion proteins and methods of use
TWI844709B (zh) 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法

Also Published As

Publication number Publication date
JP2023017806A (ja) 2023-02-07
AU2017371217A1 (en) 2019-07-25
EP3551209B1 (en) 2021-06-30
AU2020227002A1 (en) 2020-09-17
DK3551209T3 (da) 2021-08-23
AU2020227002B2 (en) 2024-02-01
JP2020503889A (ja) 2020-02-06
US10597435B2 (en) 2020-03-24
CA3046337A1 (en) 2018-06-14
HUE055417T2 (hu) 2021-11-29
LT3551209T (lt) 2021-09-10
AU2017371217B2 (en) 2020-03-19
EP3939605A1 (en) 2022-01-19
WO2018107117A1 (en) 2018-06-14
BR112019011860A2 (pt) 2019-11-12
EP3551209A1 (en) 2019-10-16
EP3551209A4 (en) 2020-06-03
US20200131243A1 (en) 2020-04-30
HRP20211334T1 (hr) 2021-11-26
CN110612112B (zh) 2024-03-29
CA3046337C (en) 2021-06-01
JP7170332B2 (ja) 2022-11-14
US20190315828A1 (en) 2019-10-17
CN110612112A (zh) 2019-12-24
US11359001B2 (en) 2022-06-14

Similar Documents

Publication Publication Date Title
IL286316A (en) New micro-dystrophins and related method of use
IL304117A (en) Anti-pvrig antibodies and methods of use
HK1258058A1 (zh) 抗tigit抗體和使用方法
HK1252858A1 (zh) 抗cll-1抗體和使用方法
HK1243102A1 (zh) 抗cd79b抗體和使用方法
IL250415B (en) Antibodies against pd-l and methods of using them
LT3551209T (lt) Insulino-fc suliejimai ir panaudojimo būdai
HRP20181359T1 (hr) Anti-jagged1 protutijela i postupci uporabe
PT3548033T (pt) Compostos e respectivos métodos de utilização
HUE047784T2 (hu) Anti-TIM3 antitestek és alkalmazási eljárások
ZA201905677B (en) Glycan-interacting compounds and methods of use
GB201814832D0 (en) Shoulder braces and methods of use
HK1258850A1 (zh) 抗tpbg抗體及使用方法
SG11201605915WA (en) Furo-3-carboxamide derivatives and methods of use
GB201416797D0 (en) Contianer and method of use thereof